Metabolic Fatty Liver Disease (MASLD) | Current Challenges and Therapeutic Solutions

Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) is currently the most common chronic liver disease worldwide and one of the main consequences of the global epidemic of obesity, type 2 diabetes mellitus, and metabolic syndrome. The continuing rise in the prevalence of these conditions has turned MASLD into a major public health problem, with significant clinical, economic, and social implications.
MASLD affects a substantial proportion of the adult population, with prevalence considerably higher among people with obesity, type 2 diabetes, and other components of metabolic dysfunction. In addition, the disease is being diagnosed increasingly often in children and adolescents, reflecting lifestyle changes and the rising prevalence of excess weight from the earliest decades of life.

Contents

Chapter I. Definition, classification, and epidemiology of MASLD
Chapter II. Pathophysiology of MASLD
Chapter III. The relationship between MASLD and metabolic diseases
Chapter IV. Diagnosis of MASLD
Chapter V. Non-pharmacological management of MASLD
Chapter VI. Pharmacological treatment and emerging therapies
Chapter VII. Prevention of disease progression and patient monitoring